Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I iPS cell-derived CTL therapy (rejT-E01) for EBV-associated lymphomas
jRCT2033250258Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2025
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rejT-E01 in EBV-positive lymphoproliferative disorder (EBV-LPD), Epstein-Barr virus infection and Lymphoma (EBV-positive), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety and tolerability (adverse events), Laboratory abnormalities and cytokine release syndrome and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
rejT-E01
03
Conditions
EBV-positive lymphoproliferative disorder (EBV-LPD)Epstein-Barr virus infectionLymphoma (EBV-positive)
Beyond the preview
Go deeper on jRCT2033250258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250258.